Evidence map›Paper›PMID 40178463›Full record

Trial reportJACC. Cardiovascular imaging2025

Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography.

Donghee Han, Evangelos Tzolos, Rebekah Park, Heidi Gransar, Mark Hyun, John D Friedman, Sean W Hayes, Louise E J Thomson, Alan C Kwan, Matthew Budoff and 8 more

Registry-linked trialAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JACC. Cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03689946. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03689946 phase3completed

Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study

Ran2019Enrolled55Registered outcomes2Posted comparisons0ConditionsCardiovascular Disease, HyperlipidemiaArms18F-NaF PET, CCTA, Evolocumab, metoprolol, nitroglycerin
Open the trial in the graph
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Coronary artery disease imaging with total-body PET.The British journal of radiology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Donghee HanDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Evangelos TzolosCentre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
Rebekah ParkDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Heidi GransarDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mark HyunDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA.
John D FriedmanDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sean W HayesDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Louise E J ThomsonDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Alan C KwanDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Matthew BudoffDepartment of Internal Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Prediman K ShahDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jacek KwiecińskiDepartment of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland.
Sarah WetzelDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Chloe FindlingDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Piotr J SlomkaDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Damini DeyDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Balaji K TamarappooDepartment of Cardiology, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
Daniel S BermanDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: daniel.berman@cshs.org.

Funding

Patient-specific Outcome Prediction from Cardiovascular Multimodality Imaging by Artificial IntelligenceR35HL161195 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Piotr J Slomka · 2022 to 2026
$5.0M
Integrated prediction of cardiovascular events by automated coronary plaque and pericoronary adipose tissue quantification from CT AngiographyR01HL148787 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI DEY, DAMINI · 2020 to 2023
$3.0M
NHLBI NIH HHS R01 HL148787NHLBI NIH HHS R35 HL161195
6 · The paper itself

Abstract

backgroundThe effects of evolocumab on the underlying coronary disease activity by positron emission tomography (PET) and coronary tree plaque composition by coronary computed tomography angiography (CTA) have not been described.

objectivesThis prospective imaging study aimed to evaluate changes in coronary plaque composition on coronary CTA and coronary microcalcification, a marker of plaque activity, on

methodsThis single-arm, prospective, open-label study enrolled patients with baseline extensive noncalcified plaque volume by coronary CTA (>440 µL overall coronary artery or >250 µL in any single plaque). All participants underwent baseline and 18-month follow-up coronary CTA and

resultsA total of 47 patients (age 61.8 ± 10.1 years, 87% male) and 196 lesions were studied. Twenty-three (48.9%) patients were asymptomatic, 16 (34%) presented with chest pain, and 8 (17%) presented with dyspnea. Four (8.5%) patients had a prior coronary artery disease history. At a mean follow-up of 18 months, there was no significant change in total plaque volume (716.2 ± 431.4 µL to 710.8 ± 456.2 µL, difference: 5.4 ± 97.4 µL; P = 0.705). Changes in plaque composition were observed, with a significant reduction in noncalcified plaque (607.3 ± 346.8 µL to 562.1 ± 337.3 µL, difference: 45.2 ± 63.8 µL; P < 0.001) and low-attenuation noncalcified plaque (37.1 ± 28.9 µL to 20.4 ± 15.4 µL, difference: 16.6 ± 23.5 µL; P < 0.001). In contrast, there was an increase in calcified plaque (108.9 ± 133.7 µL to 148.7 ± 175.3 µL, difference: 39.8 ± 56.1 µL; P < 0.001). There was a significant reduction in coronary microcalcification activity (1.35 ± 1.68 to 1.08 ± 1.37; P = 0.004) and lesion target-to-background ratio (1.73 ± 0.85 to 1.62 ± 0.83; P = 0.005).

conclusionsIn stable patients with extensive noncalcified plaque volume at baseline, 18 months of evolocumab treatment was associated with a shift toward a lower risk quantitative plaque phenotype and reduction in microcalcification activity. (Effect of Evolocumab on Coronary Atherosclerosis; NCT03689946).

Indexed as

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsCoronary Artery DiseaseCoronary VesselsPCSK9 InhibitorsPlaque, AtheroscleroticVascular CalcificationAgedComputed Tomography AngiographyCoronary AngiographyFemaleFluorine RadioisotopesHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsevolocumabFluorine RadioisotopesPCSK9 InhibitorsRadiopharmaceuticalsSodium Fluoride(18)F-NaF PETcomputed tomography angiographycoronary artery diseaseevolocumabplaque

Identifiers

PMID40178463
PMCPMC12058403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.